Wonderful news in that it is now a given that a P3 for OM will be run in both the US/EU. Thus, the deal for OM now moves the P3 acceptance from the milestone stack to the upfront monies stack, which is imperative for our current need for funds to start the P3 and fund current ops and maybe further lab work on IBD pill and K pill.
This may allow Leo to dicker a bit longer on IBD to get a much better deal which I am all for if a couple of months would mean a much more lucrative deal.
I had heard that this mtg with EMA and their approval/requirements for the P3 to be compatible w/ the USA P3 (so that patients in both trials can be used in the other trial) was upcoming and now we know the sources were right on the money.
More continued great news from the company and another major step towards our first P3, first partnership, and finally some cash in the bank.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links